Literature DB >> 20542033

Leishmania infantum chagasi: a genome-based approach to identification of excreted/secreted proteins.

Sruti DebRoy1, Alexandra B Keenan, Norikiyo Ueno, Selma M B Jeronimo, John E Donelson, Mary E Wilson.   

Abstract

The parasitic protozoan, Leishmania, survives in harsh environments within its mammalian and sand fly hosts. Secreted proteins likely play critical roles in the parasite's interactions with its environment. As a preliminary identification of the spectrum of potential excreted/secreted (ES) proteins of Leishmania infantum chagasi (Lic), a causative agent of visceral leishmaniasis, we used standard algorithms to screen the annotated L. infantum genome for genes whose predicted protein products have an N-terminal signal peptide and lack transmembrane domains and membrane anchors. A suite of 181 candidate ES proteins were identified. These included several that were documented in the literature to be released by other Leishmania spp. Six candidate ES proteins were selected for further validation of their expression and release by different parasite stages. We found both amastigote-specific and promastigote-specific released proteins. The ES proteins of Lic are candidates for future studies of parasite virulence determinants and host protective immunity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20542033      PMCID: PMC2939245          DOI: 10.1016/j.exppara.2010.06.011

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  60 in total

Review 1.  The strange case of Leishmania chagasi.

Authors:  I L Maurício; J R Stothard; M A Miles
Journal:  Parasitol Today       Date:  2000-05

2.  Pathogenic leishmania secrete antigenically related chitinases which are encoded by a highly conserved gene locus.

Authors:  A M Shakarian; D M Dwyer
Journal:  Exp Parasitol       Date:  2000-04       Impact factor: 2.011

Review 3.  Rhoptries: an arsenal of secreted virulence factors.

Authors:  Peter J Bradley; L David Sibley
Journal:  Curr Opin Microbiol       Date:  2007-11-09       Impact factor: 7.934

Review 4.  Host-pathogen interplay and the evolution of bacterial effectors.

Authors:  John Stavrinides; Honour C McCann; David S Guttman
Journal:  Cell Microbiol       Date:  2007-11-21       Impact factor: 3.715

Review 5.  Adhesion molecules and other secreted host-interaction determinants in Apicomplexa: insights from comparative genomics.

Authors:  Vivek Anantharaman; Lakshminarayan M Iyer; S Balaji; L Aravind
Journal:  Int Rev Cytol       Date:  2007

6.  The major surface protease (MSP or GP63) in the intracellular amastigote stage of Leishmania chagasi.

Authors:  Chia-Hung Christine Hsiao; Chaoqun Yao; Patricia Storlie; John E Donelson; Mary E Wilson
Journal:  Mol Biochem Parasitol       Date:  2007-10-30       Impact factor: 1.759

7.  Effects of serine protease inhibitors on viability and morphology of Leishmania (Leishmania) amazonensis promastigotes.

Authors:  R E Silva-Lopez; J A Morgado-Díaz; M A Chávez; S Giovanni-De-Simone
Journal:  Parasitol Res       Date:  2007-08-29       Impact factor: 2.289

8.  Leishmania chagasi: homogenous metacyclic promastigotes isolated by buoyant density are highly virulent in a mouse model.

Authors:  Chaoqun Yao; Yani Chen; Bayan Sudan; John E Donelson; Mary E Wilson
Journal:  Exp Parasitol       Date:  2007-07-13       Impact factor: 2.011

9.  LdARL-3A, a Leishmania promastigote-specific ADP-ribosylation factor-like protein, is essential for flagellum integrity.

Authors:  A Cuvillier; F Redon; J C Antoine; P Chardin; T DeVos; G Merlin
Journal:  J Cell Sci       Date:  2000-06       Impact factor: 5.285

10.  Comparative genomic analysis of three Leishmania species that cause diverse human disease.

Authors:  Christopher S Peacock; Kathy Seeger; David Harris; Lee Murphy; Jeronimo C Ruiz; Michael A Quail; Nick Peters; Ellen Adlem; Adrian Tivey; Martin Aslett; Arnaud Kerhornou; Alasdair Ivens; Audrey Fraser; Marie-Adele Rajandream; Tim Carver; Halina Norbertczak; Tracey Chillingworth; Zahra Hance; Kay Jagels; Sharon Moule; Doug Ormond; Simon Rutter; Rob Squares; Sally Whitehead; Ester Rabbinowitsch; Claire Arrowsmith; Brian White; Scott Thurston; Frédéric Bringaud; Sandra L Baldauf; Adam Faulconbridge; Daniel Jeffares; Daniel P Depledge; Samuel O Oyola; James D Hilley; Loislene O Brito; Luiz R O Tosi; Barclay Barrell; Angela K Cruz; Jeremy C Mottram; Deborah F Smith; Matthew Berriman
Journal:  Nat Genet       Date:  2007-06-17       Impact factor: 38.330

View more
  5 in total

Review 1.  Microbial peptidyl-prolyl cis/trans isomerases (PPIases): virulence factors and potential alternative drug targets.

Authors:  Can M Ünal; Michael Steinert
Journal:  Microbiol Mol Biol Rev       Date:  2014-09       Impact factor: 11.056

2.  The efficacy of L. (L.) chagasi excreted-secreted antigens (ESAs) for visceral leishmaniasis diagnosis is due to low levels of cross-reactivity.

Authors:  Viviana Pinedo-Cancino; Norival Kesper; Clara Lúcia Barbiéri; José Angelo Lauletta Lindoso; Eufrosina Setsu Umezawa
Journal:  Am J Trop Med Hyg       Date:  2013-01-16       Impact factor: 2.345

3.  Leptomonas seymouri and Crithidia fasciculata exoantigens can discriminate human cases of visceral leishmaniasis from American tegumentary leishmaniasis ones.

Authors:  Norival Kesper; Marta Maria G Teixeira; José Angelo L Lindoso; Clara Lúcia Barbieri; Eufrosina Setsu Umezawa
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2017-04-03       Impact factor: 1.846

Review 4.  Leishmania exosomes deliver preemptive strikes to create an environment permissive for early infection.

Authors:  Judith Maxwell Silverman; Neil E Reiner
Journal:  Front Cell Infect Microbiol       Date:  2012-01-09       Impact factor: 5.293

5.  Immunomodulatory Effects of Four Leishmania infantum Potentially Excreted/Secreted Proteins on Human Dendritic Cells Differentiation and Maturation.

Authors:  Wafa Markikou-Ouni; Sima Drini; Narges Bahi-Jaber; Mehdi Chenik; Amel Meddeb-Garnaoui
Journal:  PLoS One       Date:  2015-11-18       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.